We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
The characteristics, symptoms, diagnosis and epidemiology of chikungunya.
The profiles provide data on musculoskeletal conditions and services for local populations in England.
Travel and clinical advice on Cyclospora including characteristics, symptoms, diagnosis and epidemiology.
Travel and clinical advice on yellow fever including symptoms, diagnosis and epidemiology.
This guidance describes case definitions to inform testing and reporting of suspected mpox cases.
Clinical advice on West Nile virus including symptoms, diagnosis and epidemiology.
Information on the reporting, investigation and management of acute flaccid paralysis (AFP) and acute flaccid myelitis (AFM).
The epidemiology, symptoms, diagnosis and management of monkeypox virus infections.
The characteristics, diagnosis, management and epidemiology of necrotising fasciitis (NF).
Information and resources on musculoskeletal health conditions.
Information to assist with differentiating Lyme disease from other causes of rash, neurological or non-specific symptoms.
Healthcare professionals prescribing fluoroquinolone antibiotics (ciprofloxacin, delafloxacin, levofloxacin, moxifloxacin, ofloxacin) are reminded to be alert to the risk of disabling and potentially long-lasting or irreversible side effects. Do not prescribe fluoroquinolones for non-severe or self-limiting infections, or for mild to...
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (7 March 2024) approved the medicine rozanolixizumab (Rystiggo) to treat adults with generalised myasthenia gravis, an autoimmune disease that causes muscle weakness, which can affect multiple muscle groups throughout the...
We want to remind healthcare professionals that use of systemic (oral and injectable) NSAIDs such as ibuprofen, naproxen, and diclofenac is contraindicated in the last trimester of pregnancy (after 28 weeks of pregnancy).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).